Renaissance Technologies Portfolio holdings
Renaissance Technologies LLC, founded in 1982 by mathematician James Simons as Monemetrics and headquartered in East Setauket, New York, is a legendary quantitative hedge fund managing around $65 billion in assets as of late 2024, renowned for its pioneering use of mathematical models and algorithms in trading. Starting with currency trading and evolving into a secretive powerhouse under its flagship Medallion Fund—launched in 1988—the firm employs PhDs, physicists, and computer scientists to analyze vast datasets, executing high-frequency trades across equities, futures, and derivatives with returns averaging over 66% annually before fees from 1988 to 2018. Simons, who stepped down as chairman in 2021, built a culture of intellectual rigor, limiting Medallion to employees and insiders since 1993 while offering institutional funds like the Renaissance Institutional Equities Fund (RIEF) to outsiders. Now led by Peter Brown and Robert Mercer’s successors, Renaissance remains a benchmark for quant investing, blending academic precision with a low-profile, extraordinarily profitable legacy despite occasional regulatory scrutiny.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Baidu
BIDU
|
+$462M |
| 2 |
AGN
Allergan plc
AGN
|
+$390M |
| 3 |
AT&T
T
|
+$371M |
| 4 |
Bristol-Myers Squibb
BMY
|
+$353M |
| 5 |
NextEra Energy
NEE
|
+$326M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Tesla
TSLA
|
+$1.97B |
| 2 |
Meta Platforms (Facebook)
META
|
+$435M |
| 3 |
Pfizer
PFE
|
+$377M |
| 4 |
GE Aerospace
GE
|
+$354M |
| 5 |
Starbucks
SBUX
|
+$323M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 25.43% |
| 2 | Technology | 12.71% |
| 3 | Consumer Staples | 9.79% |
| 4 | Financials | 8.2% |
| 5 | Utilities | 8.06% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
3176
Sundial Growers
SNDL
$315M
| $133K | ﹤0.01% |
+20,750
| New | +$354K |
|
3177
Forum Energy Technologies
FET
$849M
| $132K | ﹤0.01% |
37,271
+8,489
| +29% | +$157K |
|
3178
Lipocine
LPCN
$17.9M
| $132K | ﹤0.01% |
16,183
-95,656
| -86% | -$757K |
|
3179
Ranger Energy Services
RNGR
$371M
| $131K | ﹤0.01% |
32,287
+2,801
| +9% | +$17.2K |
|
|
NBRV
3180
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
| $131K | ﹤0.01% |
910
-3,409
| -79% | -$1.04M |
|
|
NINE
3181
DELISTED
Nine Energy Service
NINE
| $130K | ﹤0.01% |
160,700
+50,500
| +46% | +$228K |
|
3182
Aehr Test Systems
AEHR
$3.22B
| $129K | ﹤0.01% |
77,299
-301
| -0.4% | -$581 |
|
3183
Destination XL Group
DXLG
$30.7M
| $128K | ﹤0.01% |
365,811
+150,523
| +70% | +$132K |
|
3184
Arcadia Biosciences
RKDA
$1.53M
| $126K | ﹤0.01% |
+1,102
| New | +$192K |
|
3185
BayCom
BCML
$335M
| $125K | ﹤0.01% |
10,400
-34,700
| -77% | -$693K |
|
3186
Capricor Therapeutics
CAPR
$228M
| $124K | ﹤0.01% |
103,615
+19,830
| +24% | +$27.7K |
|
3187
Carter Bankshares
CARE
$778M
| $124K | ﹤0.01% |
+13,487
| New | +$230K |
|
3188
Fulgent Genetics
FLGT
$526M
| $124K | ﹤0.01% |
11,521
-76,900
| -87% | -$1.07M |
|
3189
International Money Express
IMXI
$370M
| $124K | ﹤0.01% |
+13,615
| New | +$143K |
|
|
MCF
3190
DELISTED
Contango Oil & Gas Co.
MCF
| $123K | ﹤0.01% |
+82,066
| New | +$258K |
|
3191
Xenetic Biosciences
XBIO
$6.78M
| $122K | ﹤0.01% |
16,412
+4,332
| +36% | +$50.3K |
|
|
REV
3192
DELISTED
Revlon, Inc.
REV
| $122K | ﹤0.01% |
+11,196
| New | +$205K |
|
|
APM
3193
DELISTED
Aptorum Group
APM
| $121K | ﹤0.01% |
+3,304
| New | +$339K |
|
|
SOLO
3194
DELISTED
Electrameccanica Vehicles Corp. Ltd.
SOLO
| $121K | ﹤0.01% |
+116,153
| New | +$215K |
|
|
DX
3195
Dynex Capital
DX
$3.19B
| $120K | ﹤0.01% |
+11,500
| New | +$190K |
|
3196
DSS Inc
DSS
$5.52M
| $118K | ﹤0.01% |
1,067
+1,012
| +1,840% | +$139K |
|
|
CARM
3197
DELISTED
Carisma Therapeutics
CARM
| $117K | ﹤0.01% |
+10,411
| New | +$171K |
|
|
MTL.PR
3198
DELISTED
Mechel PAO American Depositary Shares (each representing one-half of a Preferred Share)
MTL.PR
| $117K | ﹤0.01% |
334,802
+9,202
| +3% | +$6.38K |
|
|
PPBT
3199
Purple Biotech
PPBT
$1.4M
| $116K | ﹤0.01% |
+189
| New | +$232K |
|
3200
US Global Investors
GROW
$37.8M
| $115K | ﹤0.01% |
118,326
+14,500
| +14% | +$17.7K |
|
Similar funds
Renaissance Technologies's Q1 2020 Portfolio in Review
As of Q1 2020, Renaissance Technologies held 4,047 positions worth $103B, down 21% from $130B the previous quarter. Its ten largest holdings account for 15% of the portfolio.
Renaissance Technologies's Q1 2020 filing shows 573 new, 1,474 increased, 1,328 reduced and 645 closed positions. Its largest new stake was AT&T: 13,563,699 shares worth $299M. The largest sale was Tesla, an estimated $1.97B.
By sector, the portfolio is most concentrated in Healthcare at 25% of assets, up from 21% a quarter earlier, followed by Technology and Consumer Staples.
- Renaissance Technologies's largest Q1 2020 buy was AT&T: 13,563,699 shares worth $299M.
- Renaissance Technologies added most to Baidu in Q1 2020, an estimated $462M increase.
- Renaissance Technologies's biggest Q1 2020 reduction was Tesla, cutting an estimated $1.97B.
- Renaissance Technologies fully exited Phillips 66 in Q1 2020, selling an estimated $214M.
- Renaissance Technologies's ten largest holdings make up 15% of its $103B portfolio in Q1 2020.
- Renaissance Technologies opened 573 new positions and closed 645 in Q1 2020.
- Renaissance Technologies's portfolio value fell 21% quarter-over-quarter to $103B.
Based on Renaissance Technologies's 13F filing for Q1 2020, filed 14 May 2020.